ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag pharma clinical trials biobusiness drug development business

Biotech Buys Autoimmune Firm for $7B
Kerry Grens | Jul 16, 2015 | 1 min read
Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.
computing a cure
Artificial Intelligence Shakes Up Drug Discovery
Bianca Nogrady | May 1, 2019 | 8 min read
The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.
Roche Buys Biotech for $8.3B
Jef Akst | Aug 27, 2014 | 1 min read
The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.
The Profits of Nonprofit
Megan Scudellari | Jan 1, 2011 | 7 min read
The surprising results when drug development and altruism collide
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Rachael Moeller Gorman | Apr 1, 2021 | 10+ min read
Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.
Antidepressant Approvals Could Herald New Era in Psychiatric Drugs
Bianca Nogrady | Oct 1, 2019 | 9 min read
The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.
Cannabis Biotech
Daniel Cossins | Dec 1, 2014 | 8 min read
As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.
Accessing Drugs for Medical Aid-in-Dying
Catherine Offord | Aug 16, 2017 | 9 min read
A fraught market for the barbiturates prescribed to terminally ill patients who choose to end their lives has physicians turning to options outside big pharma.
Another CAR-T IPO
Jef Akst | Apr 6, 2015 | 1 min read
Cellectis goes public for a whopping $228 million—nearly double the value the company filed for in February.
How the Pharma Industry Pulled Off the Pivot to COVID-19
Diana Kwon | Jul 13, 2020 | 9 min read
The urgent need for tests and therapeutics has brought companies together and pushed researchers to work at breakneck speeds.

Run a Search

ADVERTISEMENT